Treatment of acute shoulder syndrome with flurbiprofen.
A multi-dose, double-blind, randomized, placebo-controlled, multicenter study was conducted to evaluate 68 patients with acute bursitis or tendinitis following treatment with flurbiprofen (Ansaid, Upjohn) or placebo. Flurbiprofen was administered in a total daily dosage of 200 to 300 mg four times daily. Based on efficacy rating scales, flurbiprofen-treated patients had the greatest proportion of improvement at almost all time periods. They also showed statistically significant improvement compared with placebo-treated patients, according to investigators' overall assessments at all time periods. Most patients showed improvement within three to four days of treatment. Flurbiprofen was both well tolerated and effective for the relief of pain caused by bursitis or tendinitis of the shoulder.
D000293:Adolescent; D000328:Adult; D000368:Aged; D002062:Bursitis / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004341:Drug Evaluation; D005260:Female; D005480:Flurbiprofen / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010919:Placebos; D011422:Propionates / Q000627:therapeutic use*; D011897:Random Allocation; D012785:Shoulder Joint; D052256:Tendinopathy / Q000188:drug therapy*
D010919:Placebos; D011422:Propionates; D005480:Flurbiprofen